Educational Programmes

We recently delivered a virtual Experts Knowledge Share meeting discussing the Current opinions on how to identify, test and treat NTRK fusion positive cancer. Our faculty of international experts Prof. David Hong (USA), Prof. Frédérique Penault-Llorca (France), and Prof. Ezra Cohen (USA), were joined by participants from over 20 countries across the world. The slides from this meeting are now available for download.

Prof Andrea Sartore-Bianchi (NTRK CONNECT) has developed this resource with COR2ED

Watch this video to better understand the paths for solid tumour that are low and high prevalence for NTRK fusions, emphasising predictors that can inform an enrichment strategy in the diagnostic process.

NTRK CONNECT’s Key Publication Snapshot 5 is now available: This fifth Publication Snapshot in the series provides insights into on-target resistance to next-generation TRK inhibitors in NTRK fusion positive cancers.

NTRK CONNECT’s Key Publication Snapshot 4 is now available: Diagnosis and management of NTRK fusion positive sarcomas – recommendations from the World Sarcoma Network

NTRK CONNECT’s Key Publication Snapshot 3 is now available. How familiar are you with the common adverse events seen with TRK inhibitor therapy?

NTRK CONNECT’s Key Publication Snapshot 2 is now available. How familiar are you with the range of testing approaches to identify patients with NTRK fusion cancer?

NTRK CONNECT’s Key Publication Snapshot 1 is now available. What do we know in 2020 about the two approved TRK inhibitors Larotrectinib and Entrectinib?

NTRK CONNECT have partnered with SARCOMA CONNECT to describe a number of the molecular subtypes that exist in paediatric and adult sarcomas. This includes a spotlight on the potential indicators that may hint at the presence of NTRK gene fusions.

NTRK CONNECT identified NTRK Gene Fusions on the ESMO OncologyPro portal as a practical guide on how to test for NTRK gene fusions and treat with TRK inhibitors.